IVF Outcomes: What May Help and Where Evidence Is Uncertain
Key Takeaways
Your age, how your ovaries responded, how the embryos developed, and your diagnosis guide an IVF plan. After a cycle that did not work, reviewing what happened and how safe the next plan is helps more than automatically adding more treatment. Many optional add-ons (extra tests or treatments) lack convincing evidence of more live births. Healthy habits support your general health but cannot guarantee success.
Key evidence: ASRM: fertility evaluation (2026) ESHRE: ovarian stimulation (2025 update) ESHRE: add-on recommendations (2023)
Where to Start
After an unsuccessful IVF cycle, it is natural to ask whether one more test or treatment would have changed the result. The place to start is a review of what happened, rather than a longer list of treatments. Sometimes that review points to a useful change. Sometimes it finds no clear cause that can be treated.
Here, “outcome” means the chance of a live birth (a baby born alive) as well as treatment safety. A positive pregnancy test, more eggs, or better-looking embryos are not the same as a live birth.
What Usually Matters Most
Age and Ovarian Reserve
When you use your own eggs, your age is an important predictor of IVF success. Two tests help estimate how the ovaries may respond to stimulation, the medicines that help several eggs grow. One is a blood test for anti-Müllerian hormone (AMH). The other is an ultrasound count of the small follicles in the ovaries (the antral follicle count). Neither measures egg quality directly, and neither can tell you for certain whether treatment will work. The fertility evaluation guidance from the American Society for Reproductive Medicine (ASRM) recommends reading these results alongside age, medical history, and previous response.
Embryo Development
Ask your fertility team to walk you through the sequence: how many eggs were collected, how many were mature, how many fertilised, and how many embryos kept developing. This can show where a change might be worth discussing. The reason a cycle failed can still remain unclear. For more on this, see the factors that influence IVF success.
The Uterus and Tubes
Whether a finding on a scan needs surgery depends on the likely benefit, and that varies with the finding and your medical history. Fibroids that distort the uterine cavity, polyps, and adhesions each need individual assessment. ASRM’s evaluation guidance supports choosing tests to fit the person rather than giving everyone the same invasive tests.
A hydrosalpinx is a different problem. The trouble lies in the fallopian tube, which is damaged and filled with fluid. When the affected tube opens into the uterus, ASRM’s tubal surgery guidance supports discussing whether to remove or block that tube before IVF.
Male Factor
The semen analysis and the male partner’s medical history belong in the assessment too. ICSI, in which a single sperm is injected into an egg, can address certain fertilisation problems. Surgical sperm retrieval is used in specific situations, such as some cases where no sperm are found in the ejaculate. Each one answers its own problem, so neither works as a general “boost” to success. The AUA/ASRM male infertility guideline sets out the indications for each.
Advanced sperm-selection methods need their own assessment. The add-on guidance from the European Society of Human Reproduction and Embryology (ESHRE) does not recommend routine PICSI (selection based on sperm binding to hyaluronic acid), IMSI (selection under high magnification), or magnetic sperm sorting. A laboratory improvement still has to be shown to mean more live births.
The Medical Steps Worth Reviewing
A useful plan explains what is changing and why. These are the points worth reviewing:
- Stimulation and safety: match the protocol to how your ovaries are expected to respond and to your previous cycles. Plan how to reduce the risk of ovarian hyperstimulation syndrome (OHSS), an over-response of the ovaries to stimulation medicines. Both are main topics in the ESHRE ovarian stimulation guideline, updated in 2025.
- Transfer timing: decide whether a fresh transfer (in the same cycle as egg collection) is right for you, or whether freezing embryos and transferring later is safer or more suitable. Freezing all embryos lowers the risk of OHSS, so it has a place when there is a clear reason, such as a higher OHSS risk. The ESHRE add-on recommendations do not recommend it for routine use: the cumulative live-birth rate (the chance of having a baby across all transfers from one egg collection) is not better than with a fresh transfer.
- Transfer technique: ask about ultrasound guidance and a soft catheter. ASRM guidance reports that ultrasound guidance improves pregnancy and live-birth rates. It also supports soft catheters for better pregnancy rates, but live-birth data on catheter type are limited.
- Embryo number: discuss single-embryo transfer to reduce the risk of a multiple pregnancy, as addressed in the ESHRE guideline on the number of embryos to transfer. Some risk remains.
Dr. Aksoy’s Approach
When reviewing a previous IVF cycle, Dr. Senai Aksoy first looks at where difficulties arose: egg number, maturity, fertilisation, embryo development, or implantation. His point is practical: changing a drug brand without analysing why the protocol failed is not a new strategy. Even a well-reasoned plan cannot promise success.
Lifestyle: Helpful, but Not a Test of Willpower
General health and treatment safety matter. Ask for help to stop smoking, and discuss alcohol and any supplements with your team. If medication instructions are hard to follow, ask for them to be explained again. If an injection is missed or its timing is unclear, contact the clinic rather than changing the dose yourself.
Sleep, diet, and physical activity deserve attention without becoming another source of pressure. A failed cycle says nothing about how hard you tried.
Weight calls for a balanced conversation. ASRM’s obesity guidance notes that in women with obesity who ovulate, weight-loss interventions before treatment have not been shown to improve live-birth rates after IVF. Your general health and anaesthesia safety still matter, and so does the possible downside of delaying treatment. Any target weight or waiting period has to fit the individual patient.
How to Evaluate an Add-on
An add-on is an extra test or treatment offered alongside standard IVF. ESHRE’s 2023 recommendations advise against routine endometrial scratching (deliberately irritating the lining of the uterus).
The same recommendations advise against immune treatments such as Intralipid infusions (a fat emulsion) and intravenous immunoglobulin (IVIG, antibodies given into a vein) as fertility add-ons. Evidence of benefit is lacking, and there are safety concerns. This applies to their use to improve fertility outcomes, not to their use for a separate, diagnosed medical condition. If you already take an immune treatment for another condition, discuss it with the doctor who prescribed it and do not stop it yourself.
Before agreeing, ask:
- What problem in my case is this meant to address?
- Do studies in patients like me show more live births, or only a change in a laboratory result?
- What are the known risks, what is still unknown, and what are the cost and possible delay?
- What would the plan be if I chose not to have it?
You should be able to understand why something is recommended, without pressure to “try everything.” Read more about repeated IVF failure and the immune system.
At a Glance
| Decision | What to ask | Keep in mind |
|---|---|---|
| Reviewing a previous cycle | At what stage did a difficulty arise, and could a change address it? | Some failed cycles have no cause that can be found and corrected |
| Adjusting treatment | Is the aim better response, safer treatment, or more live births? | These are different outcomes |
| Treating a uterine or tubal finding | What is the diagnosis and the evidence for treating it? | The need for surgery depends on the finding |
| Changing lifestyle | What helps my health without needless delay? | Good habits support health but cannot guarantee success |
| Adding an optional treatment | What is the evidence for this intervention in my situation? | Each extra treatment needs evidence of its own |
Related Reading
- What Most Influences IVF Success?
- Ways to Improve IVF Success: Evidence-Based Strategies
- IVF, ICSI, and Natural-Cycle IVF: Which Problem Each One Solves
- Repeated IVF Failure and the Immune System: What Is Actually Known?
Frequently Asked Questions for Dr. Aksoy
After a failed or difficult IVF cycle, do optional add-ons usually increase the chance of a live birth?
After a failed IVF cycle, one of the questions I hear most is: “Doctor, what else can we add next time to improve the chance of success?” I understand that wish. But I explain that more procedures do not automatically mean a higher chance of pregnancy.
Many extras are offered — embryo glues, immune treatments, endometrial receptivity tests, growth hormone, and various laboratory technologies. Some may help in selected situations. For most of them, though, we do not have strong evidence that routine use raises live-birth rates. Some can even lead to unnecessary cost, side effects, and delays in treatment.
My approach is not to add new procedures automatically after a failed cycle. I first try to understand why the attempt may have failed. If we find a specific problem, we plan treatment for that problem. I do not think it is right to turn to unproven methods simply because the last cycle failed. What matters in IVF is not how many technologies we use, but whether they truly raise the chance of a healthy baby.
Evidence note: The ESHRE add-on recommendations do not recommend many of these extras for routine use, and the HFEA’s information for patients rates treatment add-ons on their evidence.
Do supplements such as CoQ10 or DHEA belong in an IVF plan?
After cycles with few eggs collected, or with poorer embryo development than expected, patients often ask whether they should take CoQ10 or DHEA. It is thought that CoQ10 may improve egg quality because it plays a role in cellular energy production. Some small studies have reported favourable findings for ovarian response and embryo development, but it has not yet been shown to raise live-birth rates reliably.
I am more cautious about DHEA. It has been used for years in women with low ovarian reserve, yet stronger research has not confirmed the hoped-for benefit. DHEA also has hormonal effects and possible side effects; it is not an ordinary vitamin. So I do not recommend DHEA routinely.
In suitable patients who want to use CoQ10, I may discuss it individually after explaining the uncertain benefit and the cost. Before either supplement, though, I look at the previous cycle in detail: how many follicles developed, how many mature eggs were collected, and how fertilisation and embryo development went. The most useful change for the next attempt may be adjusting the stimulation protocol or the timing of treatment, not a new supplement.
Evidence note: The ESHRE 2025 ovarian stimulation guideline does not recommend DHEA for women with a low or normal response to stimulation. The ESHRE add-on recommendations do not recommend antioxidant therapy in assisted reproduction; they do not name CoQ10 individually. For a fuller evidence review, see CoQ10, melatonin and NAC for oocyte quality.
After a failed IVF cycle, what should we review first before adding optional extras?
After a failed IVF cycle, my first step is not to order new tests. It is to review every stage of the previous treatment in detail. I start with the woman’s age, ovarian reserve, the medicines used, and how the ovaries responded. How many follicles developed? How many eggs were collected, and how many were mature? If we obtained fewer eggs than expected, why might that be?
I then look at the fertilisation rate, the sperm factor, and how the embryos developed on day 3 and day 5. If a transfer was done, I review embryo quality, the endometrium, progesterone support, and how the transfer was carried out technically.
When all of those stages look appropriate and only one embryo transfer has failed, it may often be more sensible to repeat the same well-planned approach than to launch a wide battery of investigations. If there was an unexpectedly poor ovarian response, fertilisation failure, a clear problem in embryo development, or a suspicious finding in the uterus, I direct the work-up to that point.
I do not automatically order immune tests, endometrial receptivity (ERA) testing, microbiome analysis, or sperm DNA fragmentation testing for every patient. Being able to run a test does not necessarily mean it is useful. The question that matters most to me is: will this result really change our plan, and do we have evidence that the change raises the chance of a live birth? If the answer is no, I prefer not to burden the patient with unnecessary tests.
FAQ: more questions about IVF outcomes
Is there one decisive step that improves IVF success?
No. The useful next step depends on the diagnosis and on what happened during treatment. Even after a careful review, there may be no clear explanation for a failed cycle.
Does lifestyle still matter during an IVF cycle?
Yes, for general health and treatment safety. It cannot guarantee pregnancy, and imperfect habits are not a reason to blame yourself for a failed cycle.
How should patients evaluate a suggested add-on?
Ask what the evidence shows for live births in patients like you, then ask about risks, cost, possible delay, and what happens if you decline it.
Sources
- ASRM Practice Committee. Fertility evaluation of infertile women: a committee opinion. Fertility and Sterility. 2026. DOI: 10.1016/j.fertnstert.2026.08.686.
- ASRM Practice Committee. Performing the embryo transfer: a guideline. Fertility and Sterility. 2017;107(4):882–896. DOI: 10.1016/j.fertnstert.2017.01.025.
- ASRM Practice Committee. Role of tubal surgery in the era of assisted reproductive technology: a committee opinion. Fertility and Sterility. 2021;115(5):1143–1150. DOI: 10.1016/j.fertnstert.2021.01.051.
- ASRM Practice Committee. Obesity and reproduction: a committee opinion. Fertility and Sterility. 2021;116(5):1266–1285. DOI: 10.1016/j.fertnstert.2021.08.018.
- AUA/ASRM. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II. Fertility and Sterility. 2021;115(1):62–69. DOI: 10.1016/j.fertnstert.2020.11.016.
- ESHRE Guideline Group on Ovarian Stimulation. Ovarian Stimulation for IVF/ICSI. 2025 update; summary paper Human Reproduction, 2026. DOI: 10.1093/humrep/deag018.
- ESHRE. Number of embryos to transfer during IVF/ICSI. 2023; summary paper 2024. Human Reproduction. 39(4):647–657. DOI: 10.1093/humrep/deae010.
- ESHRE Add-ons working group. Good practice recommendations on add-ons in reproductive medicine. 2023. Human Reproduction. 38(11):2062–2104. DOI: 10.1093/humrep/dead184.
- Human Fertilisation and Embryology Authority. Treatment add-ons with limited evidence. Information for patients. Accessed 7 November 2026.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.